Omnicell reports rise in Q4 revenues
The revenue for the quarter has witnessed a decline by $1.5m or 2.3% as compared to the third quarter of 2011. The revenue for the year ended 31
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).
The company said recent facilities upgrades have expanded its capabilities to include commercial scale manufacturing of Schedule II controlled substances. The Schedule II controlled substances are manufactured within